Promoted Content Promoted Content

X

Market Place

Market Place

Menu

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Prices
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              Galmed Pharmaceuticals

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              ISRAEL Israel

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Virtual Innovation Day

              Participation Not Confirmed

              Update your events

              Galmed Pharmaceuticals Announces Pricing of $10 Million Public Offering of Ordinary Shares

              Contact the Supplier

              Lead Product(s): Aramchol

              Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Aramchol

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Cantor Fitzgerald & Co

              Deal Size: $10.0 million Upfront Cash: Undisclosed

              Deal Type: Public Offering February 16, 2021

              Details:

              Galmed Pharmaceuticals' lead compound, Aramchol™, a backbone drug candidate for the treatment of NASH and fibrosis is currently in a Phase 3 registrational study.

              Galmed Pharmaceuticals

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              ISRAEL Israel

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Virtual Innovation Day

              Participation Not Confirmed

              Update your events

              Galmed Hosting KOL Symposium and Pipeline Update Aramchol Phase 3 Trial for Non-Alcoholic Steatohepatitis and Liver Fibrosis Amilo-5MER

              Contact the Supplier

              Lead Product(s): Aramchol

              Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Aramchol

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 19, 2021

              Details:

              The symposium will primarily focus on Aramchol, currently in Phase 3 for non-alcoholic steatohepatitis (NASH) and liver fibrosis, and Amilo-5MER for chronic inflammatory disorders.

              PharmaCompass__DigitalAd